



Naproxen [BSA] (DAG3370)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Product Overview	Naproxen, BSA-conjugated
Specificity	Naproxen conjugated with bovine serum albumin (BSA).
Species	N/A
Conjugate	BSA
Applications	immunohistochemistry and immunocytochemistry
Reconstitution	Reconstituted in deionized water (250 µg)
Format	Lyophilized
Size	1 mg
Preservative	None
Storage	2-8°C short term, -20°C long term

BACKGROUND

Introduction	Naproxen was originally marketed as the prescription drug Naprosyn by Syntex in 1976, and naproxen sodium was first marketed under the trade name Anaprox in 1980. It remains a prescription-only drug in much of the world. In the United States, the Food and Drug Administration (FDA) approved its use as an over-the-counter (OTC) drug in 1994; OTC preparations in the U.S. are mainly marketed by Bayer HealthCare under the trade name Aleve and generic store brand formulations. In Australia, packets of 275-mg tablets of naproxen sodium are Schedule 2 pharmacy medicines, with a maximum daily dose of five tablets or 1375 mg. In the United Kingdom, 250-mg tablets of naproxen were approved for OTC sale under the brand name Feminax Ultra in 2008, for the treatment of primary dysmenorrhoea in women aged
---------------------	---

15 to 50. Aleve became available over-the-counter in most provinces in Canada on 14 July 2009, but not Quebec, British Columbia, or Newfoundland and Labrador; it became available OTC in British Columbia in late January 2010. Bayer's Aleve Canada website advises, "If you live in the province of Quebec, please ask your pharmacist for Aleve."

Keywords

Naproxen sodium; Naproxen; Aleve; Anaprox; Antalgan; Feminax Ultra; Flanax; Inza; Midol Extended Relief; Nalgesin; Naposin; Naprelan; Naprosic; Naprosyn; Narocin; Proxen; Synflex; Xenobid
